Asperosaponin VI delays the progression of facet joint osteoarthritis by promoting mitophagy, inhibiting the cGAS/STING pathway, and attenuating chondrocyte pyroptosis - PubMed
7 hours ago
- #Mitophagy
- #Asperosaponin VI
- #Facet joint osteoarthritis
- Asperosaponin VI (ASA VI) delays facet joint osteoarthritis (FJOA) progression by promoting mitophagy, inhibiting the cGAS/STING pathway, and reducing chondrocyte pyroptosis.
- ASA VI exhibits anti-inflammatory effects and promotes mitophagy, but its mechanism in FJOA was previously unclear.
- The study used network pharmacology, a rat FJOA model, and IL-1β-induced chondrocyte model to explore ASA VI's effects.
- ASA VI was found to modulate the metabolic environment in FJOA, enhance TCA cycle activity, and promote mitophagy via the PINK1/Parkin pathway.
- ASA VI suppresses the cGAS/STING signaling pathway and reduces chondrocyte pyroptosis, making it a promising treatment for FJOA.